What is the purpose of the study?
The study will look at whether taking clozapine (Clozaril®) once a day is just as good as taking it twice a day by observing participants who are currently taking Clozapine twice daily. Participants will randomly be assigned to either the treatment as usual maintenance group (i.e, taking clozapine twice daily) or the switch group (i.e., taking clozapine once daily).
- Individuals diagnosed schizophrenia/schizoaffective disorder, receiving clozapine twice daily for 3 months
Age range: 18+
Gender: All
Ethnicity: All
What does the study involve?
- Number of contacts: 6 visits following a screening for eligibility
- Time period: 12 weeks
- Length of contacts: 1-hour visits
- Treatment offered: No
Study Location(s):
250 College St.
100 Stokes St. (Queen Site)
Investigator(s): Dr. Gary Remington
Contact Information:
- Phone: 416-535-8501 ext. 34321
- E-mail: carol.borlido@camh.ca
- Recruitment Flyer Link
Study End Date: 01 January 2027
REB number: 096/2015
Full Study Title: Switching from Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia: A Pilot, Double-Blind, Randomized Controlled Trial
PLEASE NOTE:
- Research staff cannot give medical advice over the phone.
- If you have specific questions regarding your health care, please contact your family physician.
- We regret that not everyone screened for a study will be eligible to participate
- For more information about other treatment options for mental illness or addiction offered by CAMH, visit www.camh.ca or call 416-535-8501.